Cyclin-dependent kinase 9 as a potential specific molecular target in NK-cell leukemia/lymphoma

BAY 1143572 is a highly selective inhibitor of cyclin-dependent kinase 9/positive transcription elongation factor b. It has entered phase I clinical studies. Here, we have assessed the utility of BAY 1143572 for treating natural killer (NK) cell leukemias/lymphomas that have a poor prognosis, namely...

Descripción completa

Detalles Bibliográficos
Autores principales: Kinoshita, Shiori, Ishida, Takashi, Ito, Asahi, Narita, Tomoko, Masaki, Ayako, Suzuki, Susumu, Yoshida, Takashi, Ri, Masaki, Kusumoto, Shigeru, Komatsu, Hirokazu, Shimizu, Norio, Inagaki, Hiroshi, Kuroda, Taruho, Scholz, Arne, Ueda, Ryuzo, Sanda, Takaomi, Iida, Shinsuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6269314/
https://www.ncbi.nlm.nih.gov/pubmed/30076184
http://dx.doi.org/10.3324/haematol.2018.191395

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6269314/
https://www.ncbi.nlm.nih.gov/pubmed/30076184
http://dx.doi.org/10.3324/haematol.2018.191395

Ejemplares similares